Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 49

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 49
---
ii) of Regulation S-K promulgated under the Exchange Act.

Three Months and Six Months Ended March 31, 2025

Results of Operations

Three months and six months ended March 31, 2025 and 2024

Revenues

Revenues from continuing operations were $59,065 for the three months ended March 31, 2025 and $59,064 for the same period ended 2024. $27,425 of revenue from related parties recognized during the three months ended March 31 2025 and consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did $27,425 for the period ended 2024. $31,640 of revenue recognized during both of the three months ended March 31, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Revenues from continuing operations were $118,130 for the six months ended March 31, 2025 and $118,129 for the same period ended 2024. $54,850 and $54,849 of revenue from related parties recognized during the six months ended March 31 2025 and 2024 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. $63,280 of revenue recognized during both of the six months ended March 31, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

| 39 |

Operating Expenses

Operating Expense were $172,414 for the three months ended March 31, 2025 and $ 160,135 for the same period ended 2024. The primarily operating expense for 2025 consists of $ 136,566 of Consulting & Professional expenses and $22,500 in rent. In the same period in previous year Consulting and Professional fees expenditure were $93,400 During the period ended 2024 research and development expenses amounted to $40,133 constituting the second largest expense recognized during that quarter.

Operating Expense were $292,857 For the six months ended March 31, 2025 and $ 341,982 for the same period ended 2024. The primarily operating expense for 2025 consists of $ 221,192 of Consulting & Professional expenses and $45,000 in rent. In the same period in previous year Consulting and Professional fees expenditure were $200,300 During the period ended 2024 research